# Quantification of Alpha-Gal Expression in Commercial BioProsthetic Heart Valves and Its Potential Mitigation

## TL;DR

This study measures alpha-Gal antigens in heart valves and finds a new treatment can reduce them, potentially improving valve longevity.

## Contribution

First quantitative assessment of αGal in 12 commercial heart valve models and evaluation of a polyphenol treatment to reduce antigenicity.

## Key findings

- Polyphenol treatment reduced αGal epitopes by ~99% in multiple BHV models.
- Glutaraldehyde degradation over 9 years led to 60% re-exposure of αGal antigens.
- Commercial BHVs retain significant immunogenic αGal xenoantigens.

## Abstract

Bioprosthetic heart valves (BHVs) are inherently susceptible to structural degeneration, driven by a combination of mechanical stress, lipid infiltration, glutaraldehyde-induced crosslinking instability, and progressive calcification. Recent evidence has implicated the αGal antigen (galactose-α-1,3-galactose) as an additional contributor to BHV deterioration through activation of innate immune pathways. The present study aims to: 1) perform a quantitative assessment of the residual presence of xenoantigens, specifically αGal, in a range of commercial BHV models; 2) evaluate the efficacy of an experimental polyphenol-based treatment in neutralizing these antigenic determinants; and 3) investigate the long-term stability of glutaraldehyde fixation concerning the potential re-exposure of αGal epitopes.

Twelve distinct BHV models were subjected to in vitro analysis for αGal antigen quantification both before and following application of an experimental polyphenol treatment. Additionally, glutaraldehyde-fixed bovine pericardial tissues were incubated in a physiologically mimetic, blood-like environment for up to 9 years in real-time to simulate the long-term behavior of BHV materials and assess antigen unmasking associated with glutaraldehyde degradation.

The average count of the αGal epitope in original pericardial valve models was 4.18 ± 0.72 × 1011/10 mg of tissue, whereas porcine valve-derived prostheses exhibited a higher mean value of 8.51 ± 2.17 × 1011/10 mg. Treatment with the polyphenol formulation resulted in a marked reduction (approximately 99%) in detectable αGal epitopes. Furthermore, glutaraldehyde fixed pericardial tissues subjected to prolonged incubation demonstrated up to 60% re-exposure of previously masked αGal antigens after 9 years, consistent with a progressive compromise of glutaraldehyde crosslinking integrity.

The data confirm that commercially available BHVs retain a substantial immunogenic burden attributable to αGal xenoantigens. Importantly, the overtime degradation of glutaraldehyde crosslinks facilitates the gradual re-exhibition of these epitopes, potentially undermining long-term valve performance. The pronounced efficacy of polyphenol-based treatment in inhibiting αGal antigens highlights its promise as a biocompatibility-enhancing pretreatment strategy for next-generation BHVs.

•For the first time, the residual amount of αGal epitopes has been quantified in the tissue of 12 different commercially available models of BHV.•The continuous immune stimulation following BHV implantation may be attributed to the depolymerization of glutaraldehyde, which results in the gradual exposure of new antigens. This unmasking effect may contribute to sustained high levels of circulating antibodies, as the immune system encounters newly exposed epitopes over time.•Polyphenol-based technology has demonstrated significant clinical potential reducing αGal antigen reactivity by up to 90% in multiple BHV models tested.

For the first time, the residual amount of αGal epitopes has been quantified in the tissue of 12 different commercially available models of BHV.

The continuous immune stimulation following BHV implantation may be attributed to the depolymerization of glutaraldehyde, which results in the gradual exposure of new antigens. This unmasking effect may contribute to sustained high levels of circulating antibodies, as the immune system encounters newly exposed epitopes over time.

Polyphenol-based technology has demonstrated significant clinical potential reducing αGal antigen reactivity by up to 90% in multiple BHV models tested.